Epitalon Compounding Pharmacy: How to Read a Certificate of Analysis

What Is Epitalon and Why Does the Source Matter?

Epitalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide first described by the late Russian gerontologist Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Early animal studies suggested it may extend telomere length and reduce oxidative stress markers, though no Phase III randomized controlled trial in humans has been completed and published to date. Because Epitalon is not an FDA-approved drug, every vial sold in the United States arrives through one of two legal pathways: a state-licensed compounding pharmacy operating under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act, or an unregulated "research chemical" vendor whose product carries no clinical quality guarantees whatsoever.

Why Compounding Pharmacy Status Matters

The FDA's outsourcing facility framework (503B) requires facilities to follow current Good Manufacturing Practice (cGMP) standards and submit to FDA inspection. FDA 503B outsourcing facilities are subject to inspection under 21 CFR Part 211. A 503A pharmacy, by contrast, compounds for an individual patient on receipt of a valid prescription and follows USP standards rather than cGMP, meaning quality assurance rests almost entirely on the pharmacy's internal testing program. USP's compounding standards are publicly searchable through the USP portal.

The practical consequence: a CoA from a 503B facility that has passed FDA inspection carries more evidentiary weight than one from an unaudited 503A shop, and both carry infinitely more weight than no CoA at all.

The Research-Chemical Gray Zone

"Research-grade" Epitalon sold by online peptide vendors sits entirely outside FDA oversight. The FDA has issued multiple warning letters to peptide vendors for selling unapproved drugs without a prescription and without verified purity. One 2022 FDA warning letter to a peptide distributor cited misbranded and adulterated drug violations under 21 U.S.C. 331. FDA warning letters related to peptide products are indexed here. An independent 2018 laboratory analysis published in JAMA Internal Medicine found that 7 of 44 tested "research peptide" products contained no detectable active ingredient. Review the JAMA Internal Medicine analysis at jamanetwork.com.

Understanding the Regulatory Framework Behind a Compounded Peptide CoA

Before reading a CoA line by line, a buyer needs to understand which rules the issuing pharmacy is supposed to follow. Three overlapping frameworks govern compounded sterile peptides in the US.

USP <797>: The Sterile Compounding Standard

The 2023 revision of USP <797> tightened beyond-use dating, environmental monitoring requirements, and personnel training mandates for sterile preparations. The full USP <797> revision summary is available through the FDA's compounding page. Any pharmacy producing injectable Epitalon must comply with this chapter. A CoA from a compliant pharmacy will reference the sterility test method (USP <71>) and the specific beyond-use date tied to the preparation's risk category and storage conditions.

USP <795>: Non-Sterile Preparations

Oral or topical Epitalon formulations fall under USP <795>. Non-sterile preparations do not require a sterility test, but they still require identity confirmation, potency assay, and microbial limits testing per USP <61> and <62>. USP <795> non-sterile compounding guidelines are summarized at fda.gov.

FDA DSCSA Track-and-Trace Requirements

The Drug Supply Chain Security Act (DSCSA) requires licensed dispensers to verify, track, and trace certain prescription drug products through the supply chain. While compounded preparations have partial exemptions, 503B outsourcing facilities must maintain lot-level traceability. DSCSA implementation details are at fda.gov/dscsa. When a pharmacy provides a CoA, the lot number on that document should match the lot number on the vial label. A mismatch is an immediate disqualifier.

How to Read an Epitalon Certificate of Analysis: Section by Section

A legitimate CoA has five core sections. Knowing what each section should contain takes the guesswork out of evaluation.

Section 1: Identity and Structural Confirmation

The first thing any CoA should establish is that the product is actually Epitalon. Ala-Glu-Asp-Gly has a molecular weight of 358.31 Da. The CoA must show either:

• LC-MS (liquid chromatography-mass spectrometry) confirming the observed mass matches 358.31 Da within instrument tolerance (typically ±0.5 Da), or
• Amino acid analysis confirming the correct molar ratios of alanine, glutamic acid, aspartic acid, and glycine.

A CoA that shows only an HPLC chromatogram without mass confirmation cannot rule out a structurally distinct peptide that happens to elute at the same retention time. Structural identity confirmation is non-negotiable. For analytical method validation standards, see FDA Guidance for Industry on Analytical Procedures.

Section 2: HPLC Purity

High-performance liquid chromatography measures what fraction of the detected signal corresponds to the target compound versus related impurities. For injectable peptides, 98% purity is the minimum acceptable threshold in most compounding pharmacies' own specifications. Some 503B facilities target 99% or higher.

The CoA must state:

• The HPLC method used (reverse-phase C18 is standard for small peptides)
• The detector wavelength (typically 220 nm for peptide bond absorbance)
• The purity result as a percentage with uncertainty
• The name and concentration of each identified impurity above 0.1%

A result of "98.5% purity" with no impurity breakdown is incomplete. Acetylated or oxidized peptide fragments are the most common impurities in synthetic tetrapeptides, and their presence at elevated levels changes the biological activity profile. USP general chapter <621> governs chromatography requirements for compendial testing.

Section 3: Sterility Testing

For any injectable preparation, USP <71> sterility testing is mandatory. The test exposes the sample to thioglycollate medium (for anaerobes) and soybean-casein digest medium (for aerobes and fungi) over 14 days. A valid result reads "No growth detected" or "Meets USP <71> requirements."

Important caveats:

• The 14-day incubation period means a batch of Epitalon can ship before full sterility results are available. Pharmacies often use rapid sterility methods (membrane filtration with accelerated incubation) or rely on environmental monitoring data and parametric release for same-day shipments. Ask the pharmacy which method was used.
• A sterility result more than 60 days old on a vial that has been sitting in a warehouse is not meaningful for the current product in your hands.

USP <71> sterility test requirements are referenced in the FDA's guidance on sterile drug products.

Section 4: Bacterial Endotoxin Testing

Endotoxins are lipopolysaccharide fragments from gram-negative bacterial cell walls. Even a sterile injectable can cause fever, chills, and systemic inflammation if endotoxin levels are elevated. The limulus amebocyte lysate (LAL) test, described in USP <85>, is the standard method.

For parenteral peptides, the accepted limit is generally <5 EU/mg, though the specific limit depends on the dose and route. The CoA should state:

• Test method: LAL (gel-clot, turbidimetric, or recombinant Factor C assay)
• Result in EU/mL or EU/mg
• Pass/fail determination against the specification

USP <85> bacterial endotoxin testing is described in FDA's guidance on pyrogen and endotoxin testing.

Section 5: pH, Osmolality, and Appearance

Injectable preparations must be compatible with subcutaneous or intravenous tissue. The CoA should show:

• pH between 4.5 and 8.5 for subcutaneous injections (closer to physiological 7.4 is preferable)
• Osmolality between 285 and 310 mOsm/kg for isotonic formulations
• Visual appearance: "clear, colorless solution, free of visible particulates"

A turbid or particulate-containing injectable should never be used regardless of what the CoA says. Visual inspection is a final safety check that no document can replace.

PCAB Accreditation and Third-Party Verification

The Pharmacy Compounding Accreditation Board (PCAB), administered by URAC, offers voluntary accreditation for compounding pharmacies. PCAB-accredited pharmacies must pass an on-site inspection covering quality management, testing programs, personnel training, and facility design. PCAB accreditation standards are detailed at urac.org/programs/pcab. As of 2024, fewer than 400 US compounding pharmacies hold PCAB accreditation out of an estimated 7,500 active compounding operations.

PCAB status does not guarantee a perfect CoA, but it is the strongest independently verified signal that a pharmacy operates above the minimum standard. A pharmacy that has never sought PCAB accreditation and cannot produce a CoA with third-party laboratory testing (i.e., testing performed by an ISO/IEC 17025-accredited lab rather than an in-house bench) should raise concern.

The HealthRX CoA Evaluation Framework scores a pharmacy's Epitalon documentation across five weighted categories: identity confirmation (25%), HPLC purity with impurity profile (25%), sterility with method transparency (20%), endotoxin with numeric result (20%), and physical parameters (10%). A pharmacy scoring below 70 out of 100 on this framework fails the minimum bar for clinical use.

Is Epitalon Legal in the United States?

Epitalon occupies a specific legal position. It is not a controlled substance under the DEA's scheduling framework. It is not an FDA-approved drug. Compounding it for individual patients under 503A requires a valid prescription from a licensed practitioner. Compounding it in bulk under 503B requires the pharmacy to be a registered outsourcing facility.

What the FDA Has Said About Peptide Compounding

In 2023 and 2024, the FDA updated its lists of bulk drug substances that may or may not be used in compounding under 503A and 503B. Epitalon does not currently appear on the FDA's 503B bulks list (the "Category 1" list of approved bulk substances). The current 503B bulks list is maintained at fda.gov. Its regulatory status under 503A compounding remains pharmacy-specific and subject to state board interpretation.

Several state pharmacy boards have independently restricted or clarified the compounding of unapproved peptides. Buyers should verify the dispensing pharmacy's state license status before ordering. The National Association of Boards of Pharmacy (NABP) maintains a database of non-recommended sites and state licensure status. Check pharmacy licensure through nabp.pharmacy.

Implications for the Buyer

Purchasing Epitalon from a vendor who does not require a prescription and ships without a CoA likely violates federal law regardless of how the product is marketed. The FDA's position is that unapproved drugs intended for human use, marketed without a prescription, are misbranded and adulterated under 21 U.S.C. 331 and 351. FDA's statutory authority over unapproved drugs is summarized at fda.gov/drugs/unapproved-drugs.

How to Choose a Compounding Pharmacy for Epitalon

Quality signals stack. No single factor is enough on its own, but the combination of PCAB accreditation, 503B registration or a documented 503A quality program, third-party testing by an ISO 17025-accredited laboratory, and a complete CoA (all five sections described above) defines the minimum bar for clinical use.

Red Flags That Should Stop a Purchase

• No CoA available, or a CoA that lists only purity with no endotoxin or sterility data
• CoA issued by the same entity selling the product (no independent lab)
• Purity listed as a range ("95-99%") rather than a specific result
• No prescription requirement for an injectable product
• Lot number on the vial does not match the lot number on the CoA
• Beyond-use date exceeding what USP <797> permits for the stated storage conditions

Questions to Ask Before Ordering

Ask the pharmacy directly: Which ISO 17025-accredited laboratory performs your release testing? Can you provide the full CoA including the chromatogram trace, not just the summary page? What is your endotoxin limit specification and the actual numeric result for this lot? Has this facility been inspected by the FDA or your state board in the last two years, and what was the outcome?

A pharmacy that hedges or delays on any of these answers is signaling that the answers are unfavorable. FDA guidance on compounding quality standards is available at fda.gov/compounding.

What the Science Says About Epitalon: Clinical Evidence Status

Epitalon's proposed mechanisms center on telomerase activation and antioxidant effects. A 2003 study by Khavinson et al. Published in the Annals of the New York Academy of Sciences reported telomere elongation in human somatic cells treated with Epitalon in vitro. The Khavinson 2003 report is indexed on PubMed at pubmed.ncbi.nlm.nih.gov/12851158. A 2012 study in the Bulletin of Experimental Biology and Medicine reported reduced mortality in Drosophila exposed to Epitalon. The 2012 Drosophila study is indexed at pubmed.ncbi.nlm.nih.gov/22810973.

No peer-reviewed, placebo-controlled, double-blind human trial with pre-registered endpoints has been published as of January 2025. ClinicalTrials.gov shows no currently registered Phase II or III trials for Epitalon. The Endocrine Society's 2019 Clinical Practice Guideline on growth hormone use in adults specifically cautions that "peptides promoted for anti-aging effects without Phase III human evidence should not be prescribed outside a supervised research protocol." The Endocrine Society guideline is available at academic.oup.com/jcem.

The gap between animal and in-vitro data and human clinical evidence is wide. A buyer who demands a rigorous CoA is, at minimum, ensuring that the compound they are ingesting is what it claims to be, even if the clinical evidence for that compound remains preliminary. That is not a small thing.

Telomere Research Context

Published research on telomere biology has grown substantially since Khavinson's early work. A 2015 meta-analysis in Aging Cell (N=17 studies) confirmed that shorter leukocyte telomere length associates with all-cause mortality (hazard ratio 1.21 per kilobase reduction, 95% CI 1.08-1.36). The Aging Cell meta-analysis is indexed at pubmed.ncbi.nlm.nih.gov/25735865. Whether exogenous tetrapeptides modify telomere length meaningfully in living humans remains unestablished.

Oxidative stress is a second proposed target. A 2020 review in Biomedicines assessed antioxidant peptides broadly and noted that small peptides face rapid proteolytic degradation after subcutaneous injection, which limits their bioavailability at target tissues. The Biomedicines review is at pubmed.ncbi.nlm.nih.gov/32156028. This degradation concern reinforces why purity matters: an impure product delivering unknown peptide fragments compounds an already uncertain pharmacokinetic picture.

Practical Checklist: Reading Your Epitalon CoA in Under 5 Minutes

Use this sequence every time a CoA arrives.

1. Check the lot number. It must match the vial label exactly.
2. Check the issuing laboratory. Search the lab name plus "ISO 17025 accreditation." If the lab is not accredited, stop.
3. Find the HPLC purity result. It must be 98% or higher as a specific number.
4. Find the LC-MS or amino acid analysis result. Observed mass must be 358.31 Da ±0.5 Da.
5. Find the endotoxin result. It must show a numeric EU/mg value at or below 5 EU/mg.
6. Find the sterility result. It must state "No growth detected" or "Meets USP <71>."
7. Check the beyond-use date. It must be consistent with USP <797> requirements for the storage conditions specified.
8. Check pH. It should be between 4.5 and 8.5.

Any missing line item is a reason to contact the pharmacy before use. A pharmacy that cannot fill in every line is not ready to dispense an injectable peptide.